ReviewERJ open research2018
An algorithmic approach for the treatment of severe uncontrolled asthma.
Review in ERJ open research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Inhaled corticosteroids and risk of upper respiratory tract infection in patients with asthma: a meta-analysis.Infection · 2019Pooled it
- Low IgE and absence of sensitization in non-T2 asthma: a transcriptomic and cytokine study.Frontiers in immunology · 2025Article
- Article
- Unanswered questions on the use of biologics in pediatric asthma.The World Allergy Organization journal · 2023Review
- Phenotype overlap in the natural history of asthma.European respiratory review : an official journal of the European Respiratory Society · 2023Review
- Article
- Effectiveness of bronchial thermoplasty in patients with asthma exhibiting overweight/obesity and low quality of life.The World Allergy Organization journal · 2023Article
- Roles of real-world evidence in severe asthma treatment: challenges and opportunities.ERJ open research · 2023Article
- Biological therapy management from the initial selection of biologics to switching between biologics in severe asthma.Tuberkuloz ve toraks · 2023Review
- Successful and safe treatment of severe steroid depended eosinophilic asthma with mepolizumab in a woman during pregnancy.Respiratory medicine case reports · 2023Article
- Ketone body augmentation decreases methacholine hyperresponsiveness in mouse models of allergic asthma.The journal of allergy and clinical immunology. Global · 2022Article
- Severe asthma treatment patterns: A multicenter observational study in the Gulf region.The World Allergy Organization journal · 2022Article
- The effect of Teach-back method education on the control of asthma and family care pressure of patients in Iran.Investigacion y educacion en enfermeria · 2022Article
- Clinical and Lung Function Outcomes After Anti-IgE or Anti-IL5 Therapy in Severe Asthma.Journal of asthma and allergy · 2022Article
- On stimulus persistence and human behavior: the stimulus persistence unification theory.Communicative & integrative biology · 2022Review
- Switch from Omalizumab to Benralizumab in Allergic Patients with Severe Eosinophilic Asthma: A Real-Life Experience from Southern Italy.Biomedicines · 2021Article
- Characterization of T2-Low and T2-High Asthma Phenotypes in Real-Life.Biomedicines · 2021Article
- Real-life Cretan asthma registry focused on severe asthma: On behalf of 'The Cretan registry of the use of Biologics in Severe Asthma'.Experimental and therapeutic medicine · 2021Article
- Perioperative management of patients with asthma during elective surgery: A systematic review.Annals of medicine and surgery (2012) · 2021Review
- Treating severe asthma: Targeting the IL-5 pathway.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A small subgroup of patients with asthma suffers from severe disease that is either partially controlled or uncontrolled despite intensive, guideline-based treatment. These patients have significantly impaired quality of life and although they constitute <5% of all asthma patients, they are responsible for more than half of asthma-related healthcare costs. Here, we review a definition for severe asthma and present all therapeutic options currently available for these severe asthma patients. Moreover, we suggest a specific algorithmic treatment approach for the management of severe, difficult-to-treat asthma based on specific phenotype characteristics and biomarkers. The diagnosis and management of severe asthma requires specialised experience, time and effort to comprehend the needs and expectations of each individual patient and incorporate those as well as his/her specific phenotype characteristics into the management planning. Although some new treatment options are currently available for these patients, there is still a need for further research into severe asthma and yet more treatment options.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.